Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 26, 2015 6:31 AM ET


Company Overview of Kiadis Pharma B.V.

Company Overview

Kiadis Pharma B.V., a clinical stage biopharmaceutical company, develops life-saving therapies for blood cancer patients in the United States and Europe. The company focuses on the development of a cellular therapeutic that enables partially mismatched donor stem cell transplants from family members in blood cancer patients. It offers ATIR, a cell-based medicinal product that facilitates early immune system recovery without causing life-threatening graft-versus-host-disease when administered as an adjunctive to a haploidentical stem cell transplantation. Kiadis Pharma B.V. was formerly known as Kiadis B.V. and changed its name to Kiadis Pharma B.V. in 2006. The company was founded in 1997 an...

Entrada 231-234

Amsterdam,  1114 AA


Founded in 1997


31 20 314 0250


31 20 314 0251

Key Executives for Kiadis Pharma B.V.

Chief Executive Officer
Chief Financial Officer
Managing Director
Chief Medical Officer and Senior Vice President
Corporate Secretary and General Counsel
Compensation as of Fiscal Year 2014.

Kiadis Pharma B.V. Key Developments

Kiadis Pharma B.V. Presents at BioEquity Europe 2015, May-19-2015 05:20 PM

Kiadis Pharma B.V. Presents at BioEquity Europe 2015, May-19-2015 05:20 PM. Venue: InterContinental Vienna, Vienna, Austria.

Kiadis Pharma B.V. Presents at BioCapital Europe 2015, Mar-26-2015 03:20 PM

Kiadis Pharma B.V. Presents at BioCapital Europe 2015, Mar-26-2015 03:20 PM. Venue: Sofitel Legend Amsterdam, Amsterdam, Netherlands.

Kiadis Pharma B.V. Announces Positive Interim Data from Ongoing Phase II Clinical Study with ATIRTM

Kiadis Pharma B.V. announced positive interim data from the ongoing Phase II clinical study with its product ATIRTM. ATIRTM is a cell-based product designed to enable stem cell transplantations from partially matched (haploidentical) family donors for blood cancer patients who do not have a standard of care stem cell donor available. The Phase II study is an international multi-center study in which a total of 23 leukemia patients, including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), will be enrolled and treated with ATIRTM as part of the transplant regimen. The primary endpoint of the study is the rate of Transplant Related Mortality (TRM) at 6 months after hematopoietic stem cell transplantation (HSCT). Data from the pre-specified interim analysis of the first 10 patients showed only 2 cases of TRM at 6 months post-HSCT and both TRM cases resulted from a viral infection. Overall, 6 out of the 10 patients were completely free from severe infections (grade 3-5) after ATIRTM administration and up to 6 months after the transplant. These data confirm the safety and efficacy of ATIRTM administration with no grade III-IV (life- threatening) acute Graft versus Host Disease (GvHD) occurring, despite the fact that no prophylactic immune suppressants were used. Only a limited number of grade I-II GvHD events were reported, all of which were treated successfully. Furthermore, no relapses were reported in any of the first 10 patients, with 4 out of the 10 patients in follow-up for more than one year at the time of the interim analysis. These data are in line with the data previously reported from Kiadis Pharma's Phase I/II study with 19 patients. The current study is progressing well with further enrollment of patients in Canada (Hôpital Maisonneuve-Rosemont (Montreal), Juravinski Hospital and Cancer Centre (Hamilton) and Princess Margaret Cancer Centre (Toronto)), Belgium (University Hospitals Leuven, AZ Sint Jan (Bruges) and Institut Jules Bordet (Brussels)) and Germany (University Hospital of Würzburg).

Similar Private Companies By Industry

Company Name Region
Mires B.V Europe
N.V. Organon Europe
Kiadis Pharma B.V. Europe
Basic Pharma Holding BV Europe
Diosynth B.V. Europe

Recent Private Companies Transactions

Private Placement
October 30, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kiadis Pharma B.V., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at